Peri-operative use of the calcium channel blocker nicardipine during phaeochromocytoma and paraganglioma resection was associated with 10.4% postoperative complications and 2.8% mortality.
Observational (n=105)
Does peri-operative management with nicardipine provide safe haemodynamic control and acceptable outcomes in patients undergoing surgery for phaeochromocytoma or paraganglioma?
The sole use of nicardipine for peri-operative management during phaeochromocytoma and paraganglioma resection does not prevent all haemodynamic fluctuations but is associated with low morbidity and mortality.
The peri-operative management of patients undergoing surgery for phaeochromocytoma or paraganglioma with calcium channel blockers (CCB) and their impact on postoperative morbidity and mortality were studied. The medical records of 105 patients undergoing surgery between 1991 and 2002 were analysed retrospectively. In all patients, the calcium channel blocker nicardipine was used for the peri-operative management of haemodynamic changes. Sixty-five patients (61.9%) showed transient intra-operative hypertension. Systolic blood pressure (SBP) > 220 mmHg and SBP > 180 mmHg for > 10 consecutive minutes was observed in 14 (13%) and four patients (2.8%), respectively. SBP 10 consecutive minutes occurred in 13 patients (12.3%). Eleven patients (10.4%) developed postoperative complications and three patients died (2.8%). The median (range) ICU and hospital length of stay were, respectively, 1 (0-7) day and 10 (2-35) days. The sole use of calcium channel blockers for the peri-operative management of phaeochromocytoma and paraganglioma resection does not prevent all haemodynamic changes; however, its use was associated with a low morbidity and mortality.
Lebuffe et al. (Sat,) conducted a observational in Phaeochromocytoma or paraganglioma (n=105). Calcium channel blockers (nicardipine) was evaluated on Postoperative morbidity and mortality. Peri-operative use of the calcium channel blocker nicardipine during phaeochromocytoma and paraganglioma resection was associated with 10.4% postoperative complications and 2.8% mortality.